Maria Zagorulya, BS, Koch Institute for Integrative Cancer Research, Cambridge, MA, elucidates the importance of understanding the role dendritic cells (DCs) play in eliciting an anti-tumor immune response and how they become dysfunctional in a tumor. DCs play a significant role in multiple steps of the anti-tumor immune response, including initiation of the response during priming but also later in the tumor microenvironment (TME), potentially to maintain stimulation of T-cell function. As such, Dr. Zagorulya explains that DCs may be required for T-cells to become effector cells and pursue execution of their cytotoxic function and elicit an anti-tumor response. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

свернуть